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Genital HPV genotypes are generally distinct serotypes, but whether variants within a genotype can represent serologic
subtypes is unclear. In this study we used serum from human volunteers vaccinated with HPV16 L1 VLPs from variant 114K,
to examine cross-neutralization of variants from each of the five major phylogenetic branches of HPV16. Recombinant Semliki
Forest virus-derived pseudovirions for each variant were generated and combined with serum from vaccines, and the mixture
was monitored for infectivity in a standard C127 cell focal transformation assay. Sera from all 10 VLP-immunized individuals
had neutralizing activity against each of the variant pseudovirions. For each of the sera, variant titers differed by only fourfold
or less from the median titer. Therefore, from a vaccine perspective, HPV16 variants belong to a single serotype. Vaccination
with HPV16 114K L1 VLPs generates antibodies that should confer a similar degree of protection against all known
phylogenetic branches of HPV16. © 2001 Academic PressKey Words: neutralization; HPV16; variants; pseudovirions; vaccine; VLP; serotypes; papillomavirus; immunoprophylaxis;
clinical trial.
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Cervical cancer is one of the most frequent causes of
cancer deaths in women worldwide (Pisani et al., 1999),
and human papillomavirus (HPV) has been implicated as
the major etiological agent for this disease (IARC, 1995).
Therefore a vaccine that can prevent transmission of the
virus, and thereby prevent cervical cancer, is a desirable
goal. Prior to human vaccine trials with HPV, animal
vaccine studies using animal papillomaviruses showed
that parenteral immunization with virus-like particles
(VLPs) composed of the L1 major capsid protein is ef-
fective in protecting animals against experimental chal-
lenge with a homologous genotype, but not a heterolo-
gous genotype, of virus (Breitburd et al., 1995; Chris-
tensen et al., 1996b; Kirnbauer et al., 1996; Suzich et al.,
995). The L1 VLPs possess the immunodominant neu-
ralization epitopes of the virus, and passive transfer
tudies with immune serum and immune IgG strongly
uggest that protection is mediated primarily by neutral-
zing antibodies (Breitburd et al., 1995; Suzich et al.,
995). Immunization of animals with HPV L1 VLPs also
nduces high titers of in vitro neutralizing antibodies
Lowe et al., 1997; Roden et al., 1997; Smith et al., 1995;
nckell et al., 1997; White et al., 1998). The encouraging
esults in animals led to the initiation of human clinical
rials of vaccines that may prevent transmission of HPV
1 To whom correspondence and reprint requests should be ad-
ressed at National Institutes of Health, National Cancer Institute,
aboratory of Cellular Oncology, Building 36, Room 1D-32, Bethesda,
D 20892. Fax: (301) 480-5322. E-mail: schillej@dc37a.nci.nih.gov.
361Hines et al., 1998; McNeil, 1997; Schiller, 1999; Sherman
t al., 1998).
In humans, several HPV types have been detected in
ervical cancers (Bosch et al., 1995), and it would be
mportant to protect against as many of these types as
ossible. Although there are no animal models for HPV
nfection, animals have been vaccinated with VLPs of
arious HPV types to assess the degree of capsid anti-
ody cross-reactivity between HPV types. Results from
LISAs (Kirnbauer et al., 1994), inhibition of mouse eryth-
ocyte agglutination (HAI) (Roden et al., 1995), in vitro
neutralization of authentic virus (Christensen and Krei-
der, 1990; White et al., 1998), and in vitro neutralization of
pseudovirions (Roden et al., 1996a) support the conclu-
sion that sera raised against VLPs can neutralize the
corresponding HPV type, but generally do not neutralize
other types. Exceptions to this are the limited cross-
neutralization seen between some very closely related
types such as HPV16 and 33; HPV18 and 45; and also
HPV6 and 11 (Christensen et al., 1994; Roden et al.,
1996b; White et al., 1998). Because of the lack of cross-
reactivity between types, a VLP-based vaccine will prob-
ably have to include several HPV types. HPV16 was
chosen as an initial model for some VLP-based vaccines,
since it is the HPV type found most frequently in cervical
cancer, present in about 50% of the tumors (Bosch et al.,
1995; Kirnbauer et al., 1993).
Numerous HPV16 variants have been isolated from
different geographic regions, and evidence suggests that
the evolution of these variants coincides with the migra-
tory patterns of early humans (Ho et al., 1991). The
variants have been grouped according to nucleotide ho-
0042-6822/01 $35.00
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362 PASTRANA ET AL.mology and have been placed along five major phyloge-
netic branches (or classes) (Chan et al., 1992; Yamada et
al., 1995). Nucleotide differences that result in amino
acid changes for L1 in 85 HPV16 variants map closely to
the principal neutralization epitopes of monoclonals V5
and E70 (Chen et al., 2000), which might suggest that the
variants were established to escape neutralization. In
support of this model, monoclonal E70 was able to neu-
tralize European (114K) but not Africa 2 (Z-1194)
pseudotype virions (Roden et al., 1997), and a single
amino acid change can result in the loss of V5 reactivity
(White et al., 1999). However, other studies suggest that
t least some cross-reactivity between variants is possi-
le: sera from women with naturally occurring HPV16
nfections recognized VLPs of HPV16 variants 114K and
1194 (Cheng et al., 1995), and another study with human
era also confirmed cross-reactivity between divergent
ariants (Touze et al., 1998). Regardless of what mecha-
ism induced the divergence between HPV16 variants, it
s important to determine whether the mutations affect
ntibody-mediated neutralization. It is difficult to predict
he effect of a given mutation on neutralization, since the
mmunodominant neutralizing antibodies recognize con-
ormational epitopes (Christensen et al., 1994; Chris-
ensen and Kreider, 1990; Roden et al., 1994).
In addition to the possibility of providing insight into
he selective pressures that may contribute to the phy-
ogenetic diversity between HPV16 variants, determining
he degree to which immunization with L1 VLPs of one
ariant may induce antibodies that cross-neutralize other
PV16 variants has important implications for the design
f vaccine efficacy trials and for vaccine valency. If an
PV16 L1 VLP vaccine were deficient in neutralizing
PV16 variants outside its own phylogenetic branch, it
ould be necessary in an efficacy trial to power the trial
ccording to the expected number of HPV16 infections
y variants within that single branch, or to use a multi-
alent vaccine that contained HPV16 VLPs from several
ranches. The issue of poor cross-neutralization would
e of particular concern for a monovalent HPV16 VLP
accine that was being tested in a population where the
ariant in the vaccine was not from the predominant branch
ound in that population (Ho et al., 1993). On the other hand,
he demonstration of efficient cross-neutralizing activity
cross the various phylogenetic branches of HPV16 would
mply that a monovalent vaccine would display a similar
egree of protection against the entire spectrum of HPV16
ariants.
Therefore, we sought in this study to determine
hether sera from a recent trial of human volunteers
mmunized with VLPs of the European variant 114K (Clay-
on Harro, Johns Hopkins University, manuscript submit-
ed) were able to neutralize representative variants from
ach of the five phylogenetic branches of HPV16. To
ake this determination, we first produced a series of
nfectious pseudotype virions that contained BPV1 ge-omes, which had been packaged by HPV16 L2 and the
PV16 L1 capsid protein from a specific variant (HPV/
PV pseudovirions). We then used a previously de-
cribed neutralization assay (Roden et al., 1996a) to as-
sess human sera from normal volunteers who had been
immunized with L1 VLPs from a single HPV16 variant for
their ability to neutralize the infectivity of this series of
HPV/BPV pseudovirions.
RESULTS
Assembly into VLPs and generation of pseudovirions
from seven HPV16 variants
To assess the potential for cross-variant protection, we
selected a total of seven HPV16 variants: one variant
from each of three European lineage subclasses and
one from each of the four other phylogenetic classes.
These variants are depicted in a phylogenetic tree (Fig.
1A) modified from Yamada and coworkers (1995). The
tree was originally constructed from the sequences of
FIG. 1. (A) HPV16 phylogenetic tree. Modified from Yamada et al.
(1995). Constructed from E6, L2, L1, and LCR sequences. Only those
variants used in this study are shown. The horizontal length of each
branch is proportional to the number of steps (reconstructed point
mutations) along that branch. The tree shows variant classes in larger
font, and European lineage subclasses P, As, and G131 in smaller font.
(B) Divergence in L1 amino acid sequence for HPV16 variants. Posi-
tions are shown only for those amino acids that differ from variant 114K.
Amino acids at those positions are shown for 114K using standard
single-letter amino acid designations. For other variants alternate
amino acids are shown, and empty spaces indicate the same amino
acid as 114K.E6, L2, and L1 of 30 isolates. For the current study, only
changes in the L1 sequence are relevant. When com-
363NEUTRALIZATION OF HPV16 VARIANTSpared to 114K L1, the most divergent variants were Af2
and AA, each having six amino acid substitutions (Fig.
1B). The least divergent were As and G131, which belong
to subclasses of the same branch as 114K. The se-
quence of 114K L1, the European variant used in the
vaccine, was originally reported as having an A at nu-
cleotide position 6432. Our laboratory, and others (White
et al., 1999), have since found that position to be a G. This
change results in an alanine instead of a threonine at
amino acid 266.
L1 amino acid sequence can influence the efficiency
of VLP assembly (Sasagawa et al., 1995; Kirnbauer et al.,
1993; Touze et al., 1998), and can presumably also affect
the production of infectious pseudovirions. 114K and
Z1194, from the European and Africa 2 variant classes,
respectively, have been used previously in in vitro neu-
tralization assays (Roden et al., 1997) and were shown to
yield similar numbers of focal transformation events.
However, for variants representing Af1, NA1, AA, As, and
G131, it was not known whether they would self-assem-
ble into capsids and would therefore be predicted to
provide the L1 functions required for generating infec-
tious pseudovirions. We thus first expressed each L1 in
BHK-21 cells, using a Semliki Forest Virus system (Roden
et al., 1996a). The resulting L1 proteins were purified by
sequential sucrose cushion and cesium chloride isopyc-
nic density gradient centrifugation (Kirnbauer et al., 1993)
and the assembly into VLPs verified by transmission
electron microscopy (data not shown).
We then determined whether L1 from the variants
could participate in the formation of infectious
pseudovirions. BPHE-1 cells contain multiple episomal
copies of the BPV1 genome. The formation of infectious
pseudovirions in BPHE-1 cells requires L1 and L2 coas-
FIG. 2. Focus formation induced by HPV16 pseudovirion variants in
C127 mouse cells. Pseudovirions (HPV16 capsid/BPV genome) carrying
variant L1 capsids were used to infect C127 monolayers, which were
grown 14–17 days postinfection and stained for visualization of trans-
formed foci. The variant name is shown above or below its correspond-
ing dish; numbers in parenthesis indicate the average number of foci
per dish from four dishes for each variant.sembly for packaging the BPV1 genome (Roden et al.,
1996a). We used the L2 gene from 114K for the productionof all pseudovirions, rather than create an SFV for L2 from
each variant and coexpressing it with its cognate L1 gene.
Thus, BPHE-1 cells were coinfected with an SFV that
expressed an L1 variant and an SFV that expressed the
114K L2, and pseudovirion production was measured by
testing the ability of lysates from these cells to induce
(BPV1 genome-dependent) focal transformation in C127
mouse fibroblasts (Dvoretzky et al., 1980). All L1 variants
were found to be able to use 114K L2 and to give rise to
infectious pseudovirions, as reflected by this bioassay
(Fig. 2). The number of foci induced from a given amount
of lysate was quite similar for each variant, of which the
highest number (Af2) was about four times greater than
the lowest (Af1). Analysis of additional independently
derived preparations of pseudovirions indicated that
these differences in focus forming activity were not vari-
ant-specific; coinfection of BPHE-1 cells with the same
recombinant L1 and L2 SFV stocks in separate assays
could lead to substantially differing numbers of infec-
tious particles (data not shown).
It was previously reported that the level of L1 expres-
sion can affect VLP yields (Touze et al., 1998). To examine
whether the relative levels of L1 or L2 might correlate
with the infectivity of a given preparation, extracts of the
pseudovirion lysates used in Fig. 2 were analyzed by
immunoblot for the presence of L1 and L2 (Fig. 3). The
highest levels of L1 expression were found with G131
and Af1; however, these two variants produced interme-
diate and low numbers of foci, respectively. Conversely,
the two preparations with the lowest levels of L1 expres-
sion (K and As) did not induce the lowest numbers of foci.
Thus, L1 did not seem to be the limiting factor for infec-
tious pseudovirion formation. The L2 used in these ex-
periments was from a single variant (114K), and its ex-
pression levels also did not correlate with pseudovirion
formation. L2 was expressed at low levels in the Af2
coinfections, and at high levels in NA1 coinfections,
but they yielded similar numbers of foci (126 and 123,
respectively).
FIG. 3. SFV-infected BPHE-1 cells express L1 from each variant and
114K L2. After coinfection with recombinant L1 and L2 SFV, BPHE-1 cells
were lysed by sonication. Protein extracts were subjected to 10% SDS–
polyacrylamide gel electrophoresis, transferred onto PVDF membranes,
and immunoblotted for the presence of L2 (top panel) or L1 (bottom panel).
For L2, rabbit anti-114K L2-GST polyclonal serum was used. For L1, mono-
clonal antibody CAMVIR-1 (McLean et al., 1990) was used. This monoclo-
nal antibody recognizes a linear epitope which is identical in all variants.
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364 PASTRANA ET AL.Neutralization of HPV16 variants with sera from
volunteers of a 114K L1 HPV16 VLP vaccine trial
Our laboratory is currently evaluating a prophylactic
HPV16 L1 VLP vaccine. Sera from volunteers immunized
with the 114K L1 vaccine have been shown to neutralize
114K L1 HPV16 pseudovirions in in vitro assays (Clayton
arro, Johns Hopkins University, manuscript submitted). To
ssess the degree to which the antibodies generated by
he vaccine would neutralize other HPV16 isolates, the sera
ere used to carry out titrations of in vitro neutralization of
he infectious pseudovirion variants described above. The
era tested were from 10 volunteers who had been immu-
ized with three 50-mg doses of VLPs without adjuvant, and
rom two control subjects from the same study who had
eceived the placebo (saline solution). The serum samples
ere those that had been taken 5 months after initial vac-
ination, 1 month after the third vaccination.
To assess the neutralizing activity, the sera were di-
uted 1:40 and the ability of fourfold serial dilutions to
eutralize a standard virus inoculum for each was deter-
ined (Table 1). Figure 4 shows the neutralization assay
esults for a serum which gave a neutralization titer of
40. As expected, sera from the placebo-vaccinated vol-
nteers (29 and 33) was unable to neutralize pseudoviri-
ns from any variant, even at the highest concentration
ested (1:40). By contrast, all of the sera from the volun-
eers who had been immunized with vaccine were able
o neutralize all variants tested, although the sera in-
luded those with a strong neutralizing response (i.e., 31)
nd those with a relatively weaker one (i.e., 32). Further-
T
Neutralizing Titer of 114K L1 VLP Vaccine Volunte
Volunteer 114K As G131
25 640 2560 640
26 640 2560 640
27 640 2560 640
28 2560 2560 2560
29 ,40 ,40 ,40
30 640 2560 2560
31 10,240 10,240 10,240
32 160 640 160
33 ,40 ,40 ,40
34 2560 2560 2560
35 2560 2560 2560
36 640 2560 640
V5a $1 3 106 $1 3 106 1 3 105
No. of focib 88 61 73
Note. Neutralizing titers for each vaccine volunteer are shown for va
and AA) and for two lineage subclasses of the European branch (As a
VLPs, while Volunteers 29 and 33 were placebo-vaccinated. ND, not d
a Neutralizing titer of monoclonal V5 (Christensen et al., 1996) for th
b Average number of foci seen for each variant from four positive coore, the calculated titers appeared to depend primarily
n the serum being tested, rather than on the pseudovirionvariant. Compared with the titer obtained with the 114K
variant (the variant used as the vaccine trial), the titer of any
individual serum was similar regardless of the variant ex-
amined, differing by no more than a single fourfold dilution
from what was seen with 114K. The preimmune sera from
all of the volunteers lacked neutralizing activity at 1:40, the
highest concentration tested.
Another way of evaluating similarities between vari-
ants is to measure the ability of neutralizing monoclonal
antibodies to bind the variants and to neutralize the
infectivity of the pseudovirions. In HPV16 ELISA assays,
neutralizing monoclonal V5 (Christensen et al., 1996a)
against Homologous and Heterologous Variants
Af1 Af2 NA1 AA
2560 640 640 640
2560 640 640 640
2560 640 640 640
2560 2560 2560 2560
,40 ,40 ,40 ,40
2560 640 640 2560
10,240 2560 10,240 10,240
640 160 160 640
ND ,40 ,40 ,40
2560 640 2560 2560
2560 640 2560 2560
640 160 160 640
$1 3 106 1 3 105 1 3 105 $1 3 106
29 126 123 33
rom each of the five phylogenetic branches of HPV16 (E, Af1, Af2, NA1,
1). Volunteers 25–28, 30–32, and 34–36 were immunized with 114K L1
ed.
us variants.
lates.
FIG. 4. Neutralization of pseudovirion infection by human immune
serum. BPHE-1 lysates (250 ml) containing 114KL1/L2 infectious
pseudovirions were combined with PBS (1), 1:40 dilution of placebo
vaccinated serum (3), or 1:2560 (4), 1:640 (5), 1:160 (6), 1:40 (7) serum
dilution of a 114K L1 VLP vaccinated volunteer and used to infect C127ABLE 1
er Sera
riants f
nd G13
etermincells, which were grown and processed as described in Fig. 2. Nega-
tive control (PBS without pseudovirions) (2).
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365NEUTRALIZATION OF HPV16 VARIANTSwas previously shown to block approximately 75% of the
reactivity in sera from naturally infected patients (Wang
et al., 1997), suggesting that it may recognize an immu-
nodominant epitope. To determine the presence or ab-
sence of known and/or dominant conformational
epitopes in the variants used in this study, neutralizing
monoclonals V5 and E70 were tested for their ability to
recognize the variants in VLP-based ELISAs (Kirnbauer
et al., 1994). Except for the lack of recognition of Af2 by
70, as previously noted (Roden et al., 1997), all other
ariants were recognized by both antibodies (data not
hown). The ability of V5 to neutralize all seven variants
as also tested. V5 efficiently neutralized all variants
Table 1). Thus, with rare exception, the variants behaved
imilarly in terms of binding the monoclonal antibodies
nd their ability to be neutralized by the sera from the
accinees.
nfluence of pseudovirion inoculum size on
eutralization titer
By convention, the neutralization titers for HPV16 are
he reciprocal of the highest dilution of serum able to
lock infection from a constant amount of virus (Roden et
l., 1996a; White et al., 1998). However, the amount of
irus has not been standardized as a defined unit (e.g.,
0 infectious particles), which might be used to compare
esults between laboratories, in part because the parti-
le-to-infectivity ratio may vary (Roden et al., 1996a).
Preliminary in vitro neutralization assays using monoclo-
al V5 and 114K pseudovirions suggested that neutral-
zation titers differed if the number of particles used in an
ssay was varied. In addition, when the number of foci
roduced by each variant, which varied from 30 to 130
Fig. 2 and Table 1), was considered, a trend was also
bserved when the neutralization titers of all vaccine
olunteers were compared to the 114K neutralization
iters. Neutralization titers were the same as or higher
han those seen with 114K if fewer foci were produced by
particular variant, while the titers were the same as or
ower than those seen with 114K if more foci were pro-
uced by a particular variant.
To experimentally examine the relationship between
he size of the virus inoculum and neutralization titers,
e used a single stock of 114K pseudovirions and varied
he size of the inoculum used in the neutralization assay.
ourfold serial dilutions of serum from a single HPV16
LP vaccine volunteer were combined with either high or
ow numbers of the pseudovirion focus-forming units
efore adding the mixtures to C127 monolayers. By this
ssay, an eightfold increase in the number of pseudoviri-
ns used resulted in an apparent 16-fold reduction of the
eutralizing titer (Table 2). To confirm that this effect was
either variant-specific nor serum-specific, we per-ormed similar neutralization experiments with the AA
ariant (one of 114K’s more distantly related L1 variants)
t
tnd another serum. Results similar to those obtained
ith 114K were also seen with AA, although the titers
gainst the two variants cannot be compared directly,
ince limited serum availability dictated that the sera
sed for each variant be different. A 10-fold increase in
he inoculum of the AA variant resulted in a 16-fold
eduction in the neutralizing titer for a vaccine volunteer’s
erum. In both variants an increase in the virus inoculum
esulted in an increased number of focal transformation
vents and a decrease in apparent neutralizing titer,
lthough the relationships were not strictly linear. These
esults demonstrate that the calculated neutralization
iter depends on the virus inoculum. They also suggest
hat at least some of the differences in neutralization titer
een between variants (Table 1) may be more apparent
han real, since the neutralization titer tended to corre-
ate inversely with the relative number of focus-forming
nits in the inoculum used for a particular variant.
DISCUSSION
In this study we have determined that immunization
ith L1 VLPs of a European HPV16 variant induces
ntibodies that are able to neutralize representative vari-
nts from all of the five phylogenetic branches of HPV16.
his result suggests that from a vaccine perspective, the
pectrum of HPV16 variants form a single serotype and
hat vaccination with 114K L1 VLPs is likely to confer a
imilar degree of protection against most HPV16 variants
orldwide.
We found that clinical isolates from the five branches
Yamada et al., 1995) were able to self-assemble effi-
iently into infectious pseudovirions and could utilize a
ommon L2, that of a European variant, to encapsidate
TABLE 2
Effect of Pseudovirion Level on Neutralizing Titers
114K AA
Volume
of virus
(ml)
Number
of foci
Neutralizing
titer
Volume
of virus
(ml)
Number
of foci
Neutralizing
titer
0.2 50 2560 0.025 52 640
1.6 150 160 0.250 .200 40
Note. Stocks of BPHE-1 lysates containing infectious 114K or AA
seudovirions were made. Different volumes of the indicated
seudovirion stock were combined with fourfold serial dilutions of
erum from 114K L1 VLP vaccine volunteers and used to infect C127
onolayers. For each variant, the first column shows the volume of
seudovirions used for infection; the second column shows the number
f foci observed when no serum was added; and the third column
hows the determined neutralizing titer for that volume of the
seudovirion preparation.he BPV1 genome. This observation implies that, al-
hough amino acid substitutions in L1 for a given HPV16
366 PASTRANA ET AL.variant are associated with specific substitutions in L2
(Yamada et al., 1995), the L1 substitutions do not prevent
the L1 protein from interacting productively with L2 from
a different variant. We did note some differences in
pseudovirion yields, but the differences were not variant-
specific. There was sufficient variation in the yields ob-
tained with different preparations of the same variant
that we attribute most of the variation in our system to the
complex interaction between the two separate SFV L1
and L2 viruses and the BPV genomes in the BPHE-1
cells, rather than to sequence-specific differences in L1
expression (Touze et al., 1998) or to putative differences
in the interactions between the 114K L2 and L1 from
other variants. The production of infectious pseudoviri-
ons requires that a given BPHE-1 cell be coinfected with
both SFV viruses, and infection by one SFV virus can
interfere with superinfection by another SFV virus (Singh
et al., 1997). In other studies, we have noted that such
dual infection occurs only in a minority of the BPHE-1
cells (Day et al., 1998).
The cross-neutralization assays indicated that all sera
from volunteers immunized with L1 VLPs from the 114K
European variant had neutralizing activity against all the
HPV16 variants. There was a correlation between the
relative neutralization titer of a given serum against the
114K pseudovirions and its relative titer against the other
variants, with the neutralizing activity against the 114K
variant being no more than one fourfold dilution higher
than that against the other variants.
It is likely that even the fourfold differences observed
in neutralization titer against variants other than 114K
may be largely a consequence of variables in the neu-
tralization assay, rather than an indication of lower neu-
tralizing activity against particular variants. In principle,
neutralization by the sera from volunteers immunized
with 114K L1 VLPs should be a function of the amount of
properly assembled L1 protein in a pseudovirion prepa-
ration. However, it is difficult to determine precisely what
proportion of L1 in a given preparation is sufficiently
self-assembled to bind the neutralizing antibodies. In
addition, different preparations, even of the same variant,
may have different particle-to-infectivity ratios, which
would also affect the apparent titer, although this ratio is
difficult to determine (Roden et al., 1996a). This variable
could explain, at least in part, why we did not find a strict
correlation between the amount of L1 in a preparation
and its infectivity as measured by the focal transforma-
tion assay. We also determined experimentally that the
apparent neutralization titer varied inversely with the size
of the pseudovirion inoculum, and the variants with lower
titers in Table 1, compared with those against 114K,
tended to be those with higher numbers of focus-forming
units. We therefore believe that although a fourfold dif-
ference in titer against the same variant in the same
assay may be significant, the variables inherent in the
cross-neutralization comparisons are such that fourfolddifferences in comparisons between variants may not be
biologically significant.
Several molecular epidemiology studies were previ-
ously performed on HPV16 variants, but little is known
about the selective pressures that led to the formation of
these variants (Chan et al., 1992; Ho et al., 1993; Stewart
et al., 1996). The concentration of amino acid mutations
around known neutralizing epitopes led some investiga-
tors (Chen et al., 2000) to speculate that fixation of HPV16
variants in the human population may be driven by es-
cape from neutralization. It is true that the Africa 2 variant
is unable to bind neutralizing monoclonal antibody E70
(Roden et al., 1997). However, to the extent that our
studies of the variants from each branch are represen-
tative of all members of that branch, our results strongly
suggest that the HPV16 genotype is comprised of vari-
ants that share at least one important neutralizing
epitope (V5), and that hyperimmune sera obtained by
vaccination with the 114K isolate recognizes an immu-
nodominant epitope(s) which is shared by all variants.
The failure of most of the amino acid changes in the
HPV16 L1 variants to be associated with loss of cross-
neutralization against the immunodominant 114K
epitope(s) may be accounted for by the relative strin-
gency of changes in L1 that are compatible with efficient
virion production. L1 is the most highly conserved of the
viral proteins (Yamada et al., 1995), and single amino acid
substitutions in a structurally important area of L1 can
severely compromise the efficiency of L1 self-assembly
into properly folded capsid protein (Kirnbauer et al.,
1993). Mutation “hot spots,” which generally lie on the sur-
face exposed residues of L1 pentamers (Chen et al., 2000),
are likely to be the areas where neutralizing epitopes lie,
but even these regions are structurally constrained. Only
two of the variants chosen for our studies (Z1194 and
NM.T529) contain amino acid changes that localize to the
major surface-exposed loops of L1 as reported by Chen et
al. (2000); however, changes in internal amino acids, such
as amino acid 50 (Chen et al., 2000), could presumably also
alter neutralization epitopes.
Our conclusion that, from a vaccine standpoint, HPV16
represents a single serotype needs to also be confirmed
for natural infections. However at least another HPV type,
HPV5, which is comprised of several variants, has been
shown to form a single serotype (Favre et al., 1997). HPV5
and HPV16 are members of different HPV supergroups
(Chan et al., 1995), with HPV5 being an EV-specific type
that typically infects nongenital skin, while HPV16 repre-
sents an anogenital type that typically infects the genital
skin and mucosa. Since HPV5 and HPV16 represent
evolutionarily different HPV types, it is tempting to spec-
ulate that other HPV types from which multiple variants
have been isolated, such as HPV6, HPV11, and HPV18
(Heinzel et al., 1995; Icenogle et al., 1991; Kitasato et al.,
1994; Ong et al., 1993), may also each represent a single
serotype. Consistent with this hypothesis, both HPV16
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367NEUTRALIZATION OF HPV16 VARIANTSand HPV18, which are found in different groups of PV
Supergroup A, seem to have undergone similar patterns
of evolution (Ho et al., 1993). However, it remains possi-
le that some HPV types might be comprised of more
han one serotype. It is clear from the large number of
PV types that serologically distinct genotypes do even-
ually evolve. But our results support the idea that this
oes not usually result from only one or a small number
f amino acid changes in L1.
VLPs are proving to be potent immunogens in humans,
s well as in animals (Breitburd et al., 1995; Kirnbauer et
l., 1996; Suzich et al., 1995; Zhang et al., 2000; Clayton
Harro, Johns Hopkins University, manuscript submitted).
It should be noted that the preimmune sera of the vac-
cinated volunteers whose immune sera were tested in
the current study were negative for serum antibodies
against HPV16 114KL1 VLPs, and the serum antibody
titers induced in the volunteers by the HPV16 L1 VLPs
were more than one order of magnitude higher than
those seen following natural infection with HPV16
(Cheng et al., 1995; Wang et al., 1997; Clayton Harro,
Johns Hopkins University, manuscript submitted). Also,
although L2 does contain neutralization epitopes
(Campo et al., 1997; Kawana et al., 1999; Roden et al.,
2000), these epitopes usually induce only low titers of
neutralizing antibodies and were not included in the L1
VLPs used to immunize the volunteers. It may therefore
be concluded that the efficient neutralization observed
for all the HPV16 variants was the result of immunization
with the vaccine and did not result from environmental
exposure to virions of the variants.
Studies in animals indicate that protection by VLPs
against animal papillomavirus infections is mediated
largely by neutralizing antibodies (Breitburd et al., 1995;
Suzich et al., 1995). The results obtained here with the
HPV16 variants indicate that there are sufficient cross-
reactive epitopes among the variants to permit efficient
cross-neutralization, although some variants may lack a
subset of the neutralizing epitopes (Roden et al., 1997;
White et al., 1999). These observations imply that what-
ever protection may be conferred by immunization with
HPV16 L1 VLPs from the 114K variant will extend to the
vast majority of HPV16 variants, although field trials will
be necessary to verify this prediction. The greater risk of
persistence and progression associated with some non-
114K HPV16 variants to develop CIN 2-3 (Xi et al., 1997)
underscores the need for a vaccine that can protect
against as many variants as possible.
MATERIALS AND METHODS
Construction of SFV expressing L1 from HPV16
variants
A variant from each of the three lineage subclasses of
the HPV16 European branch was selected, as well as
one variant from each of the four other phylogenetic
s
(branches (Fig. 1). The variants were: European (E) sub-
class P 114/K, European subclass Asian variant (As)
OR.7574, European subclass (G131) NM.T197, Africa 1
(Af1) OR.7587, Africa 2 (Af2) Z-1194, North American
(NA1) OR.3136, and Asian American (AA) NM.T529. The
L1 genes of 114K and Africa 2 had been previously
cloned into SFV expression vectors in our laboratory
(Roden et al., 1996a). The As, Af1, and AA variants were
provided by C. Wheeler (University of New Mexico)
(Yamada et al., 1995). The European and Africa 2 variants
were cloned into the BamHI site of pSFV 1 (Life Tech-
nologies, Gaithersburg, MD). As, Af1 and AA variants
were directionally subcloned from the pCR2 vector into
the BglII and HindIII sites of pBluescript, and further
subcloned into the ApaI and NotI sites of the pSFV 4.2
vector (Life Technologies). Confirmation of the DNA se-
quence of each variant was performed by double-pass
sequencing through regions of sequence divergence.
Site-directed mutagenesis was used to obtain the
G131 and NA1 variants. The 114K and Af1 variants cloned
in pBluescript (Stratagene, La Jolla, CA) were used as
templates to make the G131 and NA1 variants, respec-
tively. Divergent nucleotides in 114K and G131, compared
with Af1 and NA1, which did not result in amino acid
changes were ignored. For G131, mutagenesis produced
the necessary I191L codon change; for NA1, mutagenesis
resulted in the desired T353P codon change. The G131 and
NA1 variants were also subcloned from pBluescript into the
ApaI and NotI sites of pSFV 4.2. Double-pass sequencing of
the amplified region confirmed that the PCR procedure had
not generated unintended mutations.
Generation of HPV16 pseudotype virions
BHK-21 cells and BPHE-1 cells were grown in com-
plete Dulbecco’s minimal essential medium (DMEM)
containing 10% FBS and penicillin/streptomycin. Recom-
binant L1 SFV stocks from each variant were generated
as described previously (Roden et al., 1996a). Briefly, 8
mg of recombinant pSFV-1 and Helper 2 plasmids were
linearized with SpeI (Life Technologies). Recombinant
pSFV 4.2 plasmids were linearized with NruI (New En-
gland Biolabs; Beverly, MA). DNA was phenol:chloroform
extracted, ethanol-precipitated, and resuspended in TE.
DNA (2 mg) served as a template for an in vitro transcrip-
tion reaction, using SP6 RNA polymerase (Life Technol-
ogies). Helper 2 RNA (20 ml) and the recombinant pSFV
RNA (20 ml) were electroporated into 10 million BHK-21
cells. After electroporation, BHK-21 cells were plated and
incubated in a T-175 flask for 24 h in 30 ml medium.
Supernatants were collected and cleared by a 10-min
centrifugation at 1000 g, and stored at 280°C until used.
he L2 SFV stock used for all coinfections was from the
uropean variant 114K. L1 (1 ml) and L2 (0.25 ml) SFV
tocks were mixed together, activated with chymotrypsin
10 mg/ml; Boehringer-Mannheim, Indianapolis, IN), and
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368 PASTRANA ET AL.used to coinfect 14 million BPHE-1 cells (which contain
BPV1 episomes) for 2 h at 37°C. Complete DMEM re-
placed the infectious material, and cells were incubated
for 24 h, scraped, pelleted by centrifugation, and kept at
280°C until used.
Vaccine sera
Sera were obtained from 12 healthy volunteers en-
rolled in a phase I HPV16 L1 VLP vaccine trial of the 114K
variant (Clayton Harro, Johns Hopkins University, manu-
script submitted). Ten of the volunteers had received
intramuscular injections of 50 mg VLP vaccine without
adjuvant at 0, 1, and 4 months. Two of the volunteers had
received three placebo injections of saline in the same
study. The serum samples used in the current studies
were those taken 1 month after the third injection. They
were stored at 220°C until used.
eutralization assay
Neutralization of the infectious pseudotyped virions
as assessed as described (Roden et al., 1996a). Briefly,
he stored pellets from BPHE-1 cells that had been coin-
ected with recombinant SFV that express 114K L2 and
n L1 variant were sonicated in 1 ml PBS just prior to
ddition of human sera and infection of C127 cells. Ali-
uots of this solution were mixed for 1 h at 4°C with PBS,
r with fourfold serial dilutions of serum starting with a
:40 dilution. C127 clone C cells, which had been plated
he previous day with 1 3 105 cells/60-mm dish, were
sed in the infectivity assay. The pseudovirus/PBS or
seudovirus/serum combination was added to the cells for
h at 37°C, and then replaced with DMEM and 10% fetal
ovine serum. The cells were fed twice weekly for 14–18
ays, then stained with 2.5% methylene blue, 0.5% carbol
uchsin (w/v) in methanol for visualization of foci. The neu-
ralization titer was defined as the reciprocal of the highest
erum dilution that was able to reduce the number of foci
nduced by the pseudovirions by at least 50%.
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